Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes

Pharmacology and Toxicology

Volumn 86, Issue 6, 2000, Pages 250-256

  Beckmann Knopp, Svane ^a   Rietbrock, Stephan ^a   Weyhenmeyer, Roland ^b   Böcker, Ronald H ^c   Beckurts, K Tobias ^c   Lang, Werner ^b   Hunz, Miriam ^a   Fuhr, Uwe ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Madaus AG   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; ERYTHROMYCIN; MEPHENYTOIN; NIFEDIPINE DERIVATIVE; SILIBININ; WARFARIN;

ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IC 50; LIVER MICROSOME; PRIORITY JOURNAL; SPECTROSCOPY;

EID: 0034045694     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0901-9928.2000.860602.x     Document Type: Article

References (42)

1. Albano, E., S. W. French & M. Ingelman-Sundberg: Hydroxyethyl radicals in ethanol hepatotoxicity. Front. Biosci. 1999, 4, D533-D540.
2. Beckmann-Knopp, S., S. Rietbrock, R. Weyhenmeyer, R. Böcker, K. T. Beckurts, W. Lang & U. Fuhr: Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacology & Toxicology, 1999, 85, 299-304.
3. Bertz, R. J., G. R. Grannemann: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 1997, 32, 210-258.
4. Böcker, R. H. & F. P. Guengerich: Oxidation of 4-aryl-and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immuno-chemical evidence for the involvement of a form of cytochrome P-450. J. Med. Chem. 1986, 29, 1596-1603.
5. Committee for Proprietary Medicinal Products: Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95). The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. London, 17 December 1997.
6. Dai, R., K. A. Jacobson, R. C. Robinson & F. K. Friedman: Differential effects of flavonoids on testosterone-metabolizing cytochrome P450s. Life Sci. 1997, 61, PL75-PL80.
7. Daly, A. K.: Molecular basis of polymorphic drug metabolism. J. Mol. Med. 1995, 73, 539-553.
8. Dehmlow, C., J. Erhard & H. de Groot: Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996, 23, 749-754.
9. Down, W. H., L. F. Chasseaud & R. K. Grundy: Effect of silybin on the hepatic microsomal drug-metabolising enzyme system in the rat. Arzneimittelforsch. 1974, 24, 1986-1988.
10. Edenharder, R., R. Rauscher & K. L. Platt: The inhibition by flavonoids of 2-amino-3-methylimidazo[4,5-f]quinoline metabolic activation to a mutagen: a structure-activity relationship study. Mutat. Res. 1997, 379, 21-32.
11. Flora, K., M. Hahn, H. Rosen & K. Benner: Milk thistle (Silybum marianum) for the therapy of liver disease. Amer. J. Gastroenterol. 1998, 93, 139-143.
12. Fromm, M. F., D. Busse, H. K. Kroemer & M. Eichelbaum: Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin. Hepatology 1996, 24, 796-801.
13. Fuhr, U. Drug interactions with grapefruit juice: Extent, probable mechanism, and clinical relevance. Drug Safely 1998, 18, 251-272.
14. Fuhr, U., M. Weiss, H. K. Kroemer, G. Neugebauer, H. Rameis, W. Weber & B. G. Woodcock: Systematic screening for pharmacocinetic interactions during drug development. Int. J. Clin. Pharmacol. Therap. 1996a, 34, 139-151.
15. Fuhr, U., K. L. Rost, R. Engelhardt, M. Sachs, D. Liermann, C. Belloc, P. Beaune, S. Janezic, D. Grant, U. A. Meyer & A. H. Staib: Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996b, 6, 159-176.
16. 1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990, 11, 2275-2279.
17. Guengerich, F. P. & T. Shimada: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 1991, 4, 391-407.
18. Kharasch, E. D., D. Hankins, D. Mautz & K. E. Thummel: Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996, 347, 1367-1371.
19. Kinirons, M. T., D. O'Shea, T. E. Downing, A. T. Fitzwilliam, L. Jollenbeck, J. D. Groopmann, G. R. Wilkinson & A. J. J. Wood: Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin. Pharm. Ther. 1993, 54, 621-629.
20. Koley, A. P., R. C. Robinson & F. K. Friedmann: Cytochrome P450 conformation and substrate interaction as probed by CO binding kinetics. Biochimie 1996, 78, 706-713.
21. Koley, A. P., R. C. Robinson, A. Markowitz & F. K. Friedmann: Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem. Pharmacol. 1997, 53, 455-460.
22. Leber, H. W., & S. Knauff: Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforsch. 1976, 26, 1603-1605.
23. Lee, H., H. Yeom, Y. G. Kim, C. N. Yoon, C. Jin, J. S. Choi, B. R. Kim & D. H. Kim: Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem. Pharmacol. 1998, 55, 1369-1375.
24. Leng-Peschlow, E. & A. Strenge-Hesse: Die Mariendistel (Sylibum marianum) und Silymarin als Lebertherapeutikum. Z. Phytother. 1991, 12, 162-174.
25. Letteron, P., G. Labbe, C. Degott, A. Berson, B. Fromenty, M. Delaforge, D. Larrey & D. Pessayre: Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem. Pharmacol. 1990, 39, 2027-2034.
26. Lorenz, D., W. H. Mennicke & W. Behrendt: Untersuchungen zur Elimination von Silymarin bei cholezystektomierten Patienten. 2. Mitteilung: Biliäre Elimination nach mehrfacher oraler Gabe. Planta Med. 1982, 45, 216-223.
27. Machicao, F. & J. Sonnenbichler: Mechanism of the stimulation of RNA synthesis in rat liver nuclei by silybin. Hoppe Seylers Z. Physiol. Chem. 1977, 358, 141-147.
28. Miguez, M. P., I. Anundi, L. A. Sainz-Pardo & K. O. Lindros: Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem. Biol. Interact. 1994, 91, 51-63.
29. 4-induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol. 1989, 3, 183-191.
30. Münter, K., D. Mayer & H. Faulstich: Characterization of a transporting system in rat hepatocytes. Studies with competitive and non-competitive inhibitors of phalloidin transport. Biochim. Biophys. Acta 1986, 860, 91-98.
31. Muriel, P., T. Garciapina, V. Perez-Alvarez & M. Mourelle: Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol. 1992, 12, 439-442.
32. Nash, T.: The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J. 1953, 55, 416-421.
33. Riley, R. J. & D. Howbrook: In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin. J. Pharmacol. Toxicol. Meth. 1997, 38, 189-193.
34. Siegers, C. P., A. Frühling & M. Younes: Influence of dithiocarb, (+)-catechin and silybine on halothane hepatotoxicity in the hypoxic rat model. Acta pharmacol. et toxicol. 1983, 53, 125-129.
35. Siess, M. H., J. Leclerc, M. C. Canivenc-Lavier, P. Rat & M. Suschetet: Heterogenous effects of natural flavonoids on monooxygenase activities in human and rat liver microsomes. Toxicol. Appl. Pharmacol. 1995, 130, 73-78.
36. Tateishi, T., M. Watanabe, H. Moriya, S. Yamaguchi, T. Sato & S. Kobayashi: No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem. Pharmacol. 1999, 57, 935-939.
37. Ubeda, A., M. L. Esteve, M. J. Alcaraz, K. H. Cheeseman & T. F. Slater: Effects of flavonoids on cytochrome P-450 from rat liver microsomes: Inhibition of enzyme activities and protection against peroxidative damage. Phytotherapy Research 1995, 9, 416-420.
38. Ueng, Y.-F., T. Kuwabara, Y.-J. Chun & F. P. Guengerich: Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997, 36, 370-381.
39. Valenzuela, A. & R. Guerra: Protective effect of the flavonoid silybin dihemisuccinate on the toxicity of phenylhydrazine on rat liver. FEBS 1985, 181, 291-294.
40. Valenzuela, A., J. C. Bustamante, C. Videla & R. Guerra: Effect of silybin dihemisuccinate on the ethanol metabolizing systems of the rat liver. Cell Biochem. Func. 1989, 7, 173-178.
41. Wang, R. W., D. J. Newton, T. D. Scheri & A. Y. H. Lu: Human cytochrome P450 3A4-catalyzed testosterone 6-beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab. Dispos. 1997, 25, 502-507.
42. Weyhenmeyer, R., H. Mascher & J. Birkmayer. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992, 30, 134-138.